Australian anticancer research presented at FIP conference

A prototype of a new class of well-tolerated anticancer agents, called CTU, has been developed by pharmaceutical scientists in Australia, and the research presented at the FIP conference. Research showing the effect of the CTU prototype, in an animal model of breast cancer and on a human breast cancer cell line, was presented today at

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacist numbers growing: International Pharmaceutical Federation
Next Cost a barrier to GP visits, filling scripts for some: new data